Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Immundiagnostik AG

Immundiagnostik AG s a globally operating diagnostics company that focuses on the development and production of innov... read more Featured Products: More products

Download Mobile App





Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

Immundiagnostik AG (Bensheim, Germany) is presenting its new PCR test MutaPLEX RespiraScreen4_Diff_seqc for the first time at this year's MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More...

The test kit developed by Immundiagnostik is a further development of the existing products MutaPLEX RespiraScreen1 and MutaPLEX Coronavirus and represents a comprehensive real-time PCR diagnostic tool that efficiently, conveniently and reliably masters the expected respiratory diagnostic challenge in every new winter season.

The MutaPLEX RespiraScreen4_Diff_seqc real-time PCR test can be used to detect three different respiratory pathogens highly efficiently in just one approach: Coronavirus, Influenza Virus and RSV=Respiratory Syntial Virus. The innovative combination of two basic PCR techniques, namely qualitative amplification followed by melting curve analysis, allows the respective pathogens to be detected and differentiated in the same experiment. This means that in case of positivity (i.e. in the first step "amplification") in the case of coronavirus two different CoV-2 genes (S=Spike & E=Envelope) are specifically detected and in the case of influenza and RSV respectively the subtypes A and subtypes B are specifically detected. In all three cases, the distinction is made in the second step of the "melting curve analysis".

In addition, the entire diagnostic process is rounded off by the verification of the original sample collection by means of the detection of a human housekeeping gene. In times of pandemic coronalage, which has been ongoing for more than two years now, this is still essential, as the collection of respiratory pathogens from the nasal or oral/pharyngeal region may be suboptimal, resulting in inefficient sample collection. In these rare but not excludable cases, false-negative results in subsequent PCR diagnostics in the laboratory/testing center are inevitably the consequence.

Amplification of the human housekeeping gene on a separate detection channel of the real-time PCR instrument used provides an excellent means of controlling this situation. Detection of the human housekeeping gene provides assurance not only to the processing laboratory, but also to the specimen-submitting physician (and, not least, to the specimen-taking staff of the testing center) that the clinical source material collected and transferred to the laboratory met the requirements of correct specimen collection via swab smear. If the household gene amplification is strongly reduced or missing, the PCR result is not valid and a diagnosis of the patient sample is not possible. As a consequence, a new sample must be requested.

Related Links:
Immundiagnostik AG


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.